National Health (Weighted average disclosed price—supplementary disclosure cycle A) Determination 2013 (PB 24 of 2013)
as amended
made under subsection 99ADB(4) and paragraph 99ADH(1)(aa) of the
National Health Act 1953
Compilation start date: 9 July 2013
Includes amendments up to: PB 38 of 2013
About this compilation
This compilation
This is a compilation of the National Health (Weighted average disclosed price—supplementary disclosure cycle A) Determination 2013 (PB 24 of 2013) as in force on 9 July 2013. It includes any commenced amendment affecting the compilation to that date.
This compilation was prepared on 16 August 2013.
The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of each amended provision.
Uncommenced amendments
The effect of uncommenced amendments is not reflected in the text of the compiled law but the text of the amendments is included in the endnotes.
Application, saving and transitional provisions for provisions and amendments
If the operation of a provision or amendment is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.
Modifications
If a provision of the compiled law is affected by a modification that is in force, details are included in the endnotes.
Provisions ceasing to have effect
If a provision of the compiled law has expired or otherwise ceased to have effect in accordance with a provision of the law, details are included in the endnotes.
Contents
1 Name of Determination
2 Commencement
3 Definitions
4 Weighted average disclosed price for brands of pharmaceutical items—unadjusted price reduction is at least 10%
5 Weighted average disclosed price for brands of pharmaceutical items—unadjusted price reduction is less than 10%
6 Adjusted approved ex‑manufacturer price for brands of pharmaceutical items—unadjusted price reduction is at least 10%
7 Reduction Day
Schedule 1—Brands of pharmaceutical items—unadjusted price reduction is at least 10%
Schedule 2—Brands of pharmaceutical items—unadjusted price reduction is less than 10%
Endnotes
Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history
Endnote 5—Uncommenced amendments [none]
Endnote 6—Modifications [none]
Endnote 7—Misdescribed amendments [none]
Endnote 8—Miscellaneous [none]
1 Name of Determination
(1) This Determination is the National Health (Weighted average disclosed price—supplementary disclosure cycle A) Determination 2013.
(2) This Determination may also be cited as PB 24 of 2013.
2 Commencement
This Determination commences on the day after it is registered.
3 Definitions
In this Determination:
Act means the National Health Act 1953.
adjusted approved ex‑manufacturer price has the same meaning as in subsection 99ADB(1) of the Act.
supplementary disclosure cycle A has the same meaning as in regulation 37EB(2)(c) of the National Health (Pharmaceutical Benefits) Regulations 1960.
unadjusted price reduction has the same meaning as in subsection 99ADB(1) of the Act.
weighted average disclosed price has the same meaning as in subsection 99ADB(1) of the Act.
4 Weighted average disclosed price for brands of pharmaceutical items—unadjusted price reduction is at least 10%
For subsection 99ADB(4) of the Act, the weighted average disclosed price specified in column 3 of an item in Schedule 1 is the weighted average disclosed price for the brand of pharmaceutical item specified in column 2 of the same item in Schedule 1.
5 Weighted average disclosed price for brands of pharmaceutical items—unadjusted price reduction is less than 10%
For subsection 99ADB(4) of the Act, the weighted average disclosed price specified in column 3 of an item in Schedule 2 is the weighted average disclosed price for the brand of pharmaceutical item specified in column 2 of the same item in Schedule 2.
6 Adjusted approved ex‑manufacturer price for brands of pharmaceutical items—unadjusted price reduction is at least 10%
For paragraph 99ADB(4) of the Act, the adjusted approved ex‑manufacturer price for a brand of pharmaceutical item specified in column 2 of Schedule 1 is an amount equal to the amount of the weighted average disclosed price of that brand of pharmaceutical item determined under section 4 of this instrument.
7 Reduction Day
For paragraph 99ADH(1)(aa) of the Act, a brand of pharmaceutical item in a supplementary disclosure cycle A with a data collection period ending at the end of 31 January 2013 which is mentioned in Schedule 1 or 2 has a reduction day of 1 August 2013.
Schedule 1—Brands of pharmaceutical items—unadjusted price reduction is at least 10%
Column 1 | Column 2 | Column 3 | ||||
Item | Brand of Pharmaceutical Item | Weighted average disclosed price | ||||
| Drug | Form | Manner of administration | Brand |
| |
1 | Dexamethasone | Injection containing dexamethasone sodium phosphate equivalent to 4 mg dexamethasone phosphate in 1 mL | Injection | Dexmethsone | 6.77 | |
2 | Dexamethasone | Injection containing dexamethasone sodium phosphate equivalent to 4 mg dexamethasone phosphate in 1 mL | Injection | Hospira Pty Limited | 6.77 | |
3 | Dexamethasone | Injection containing dexamethasone sodium phosphate equivalent to 8 mg dexamethasone phosphate in 2 mL | Injection | Dexmethsone | 12.3 | |
4 | Dexamethasone | Injection containing dexamethasone sodium phosphate equivalent to 8 mg dexamethasone phosphate in 2 mL | Injection | Hospira Pty Limited | 12.3 | |
5 | Temozolomide | Capsule 100 mg | Oral | Orion Temozolomide | 455.17 | |
6 | Temozolomide | Capsule 100 mg | Oral | Temodal | 455.17 | |
7 | Temozolomide | Capsule 100 mg | Oral | Temizole 100 | 455.17 | |
8 | Temozolomide | Capsule 100 mg | Oral | Astromide | 455.17 | |
9 | Temozolomide | Capsule 140 mg | Oral | Astromide | 627.72 | |
10 | Temozolomide | Capsule 140 mg | Oral | Orion Temozolomide | 627.72 | |
11 | Temozolomide | Capsule 140 mg | Oral | Temodal | 627.72 | |
12 | Temozolomide | Capsule 140 mg | Oral | Temizole 140 | 627.72 | |
12A | Temozolomide | Capsule 180 mg | Oral | Temodal | 795.30 | |
13 | Temozolomide | Capsule 20 mg | Oral | Astromide | 106.25 | |
14 | Temozolomide | Capsule 20 mg | Oral | Temizole 20 | 106.25 | |
15 | Temozolomide | Capsule 20 mg | Oral | Orion Temozolomide | 106.25 | |
16 | Temozolomide | Capsule 20 mg | Oral | Temodal | 106.25 | |
17 | Temozolomide | Capsule 250 mg | Oral | Astromide | 1081.44 | |
18 | Temozolomide | Capsule 250 mg | Oral | Temodal | 1081.44 | |
19 | Temozolomide | Capsule 250 mg | Oral | Temizole 250 | 1081.44 | |
20 | Temozolomide | Capsule 250 mg | Oral | Orion Temozolomide | 1081.44 | |
21 | Temozolomide | Capsule 5 mg | Oral | Temizole 5 | 36.14 | |
22 | Temozolomide | Capsule 5 mg | Oral | Astromide | 36.14 | |
23 | Temozolomide | Capsule 5 mg | Oral | Orion Temozolomide | 36.14 | |
24 | Temozolomide | Capsule 5 mg | Oral | Temodal | 36.14 | |
Schedule 2—Brands of pharmaceutical items—unadjusted price reduction is less than 10%
Column 1 | Column 2 | Column 3 | |||
Item | Brand of Pharmaceutical Item | Weighted average disclosed price | |||
| Listed Drug | Form | Manner of administration | Brand |
|
1 | Dexamethasone | Eye drops 1 mg per mL, 5 mL | Application to the eye | Maxidex | 3.38 |
2 | Dexamethasone | Tablet 4 mg | Oral | Dexmethsone | 4.45 |
3 | Dexamethasone | Tablet 500 micrograms | Oral | Dexmethsone | 1.79 |
Endnotes
Endnote 1—About the endnotes
The endnotes provide details of the history of this legislation and its provisions. The following endnotes are included in each compilation:
Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history
Endnote 5—Uncommenced amendments
Endnote 6—Modifications
Endnote 7—Misdescribed amendments
Endnote 8—Miscellaneous
If there is no information under a particular endnote, the word “none” will appear in square brackets after the endnote heading.
Abbreviation key—Endnote 2
The abbreviation key in this endnote sets out abbreviations that may be used in the endnotes.
Legislation history and amendment history—Endnotes 3 and 4
Amending laws are annotated in the legislation history and amendment history.
The legislation history in endnote 3 provides information about each law that has amended the compiled law. The information includes commencement information for amending laws and details of application, saving or transitional provisions that are not included in this compilation.
The amendment history in endnote 4 provides information about amendments at the provision level. It also includes information about any provisions that have expired or otherwise ceased to have effect in accordance with a provision of the compiled law.
Uncommenced amendments—Endnote 5
The effect of uncommenced amendments is not reflected in the text of the compiled law, but the text of the amendments is included in endnote 5.
Modifications—Endnote 6
If the compiled law is affected by a modification that is in force, details of the modification are included in endnote 6.
Misdescribed amendments—Endnote 7
An amendment is a misdescribed amendment if the effect of the amendment cannot be incorporated into the text of the compilation. Any misdescribed amendment is included in endnote 7.
Miscellaneous—Endnote 8
Endnote 8 includes any additional information that may be helpful for a reader of the compilation.
Endnote 2—Abbreviation key
ad = added or inserted | pres = present |
am = amended | prev = previous |
c = clause(s) | (prev) = previously |
Ch = Chapter(s) | Pt = Part(s) |
def = definition(s) | r = regulation(s)/rule(s) |
Dict = Dictionary | Reg = Regulation/Regulations |
disallowed = disallowed by Parliament | reloc = relocated |
Div = Division(s) | renum = renumbered |
exp = expired or ceased to have effect | rep = repealed |
hdg = heading(s) | rs = repealed and substituted |
LI = Legislative Instrument | s = section(s) |
LIA = Legislative Instruments Act 2003 | Sch = Schedule(s) |
mod = modified/modification | Sdiv = Subdivision(s) |
No. = Number(s) | SLI = Select Legislative Instrument |
o = order(s) | SR = Statutory Rules |
Ord = Ordinance | Sub-Ch = Sub-Chapter(s) |
orig = original | SubPt = Subpart(s) |
par = paragraph(s)/subparagraph(s) |
|
sub-subparagraph(s) |
|
Endnote 3—Legislation history
Title | FRLI registration | Commencement | Application, saving |
PB 24 of 2013 | 26 Apr 2013 (see F2013L00688) | 27 Apr 2013 |
|
PB 38 of 2013 | 8 July 2013 (see F2013L01328) | 9 July 2013 | — |
Endnote 4—Amendment history
ad. = added or inserted am. = amended rep. = repealed rs. = repealed and substituted exp. = expired or ceased to have effect | |
Provision affected | How affected |
Sch 1 |
|
Sch 1................... | am PB 38 of 2013 |
Endnote 5—Uncommenced amendments [none]
Endnote 6—Modifications [none]
Endnote 7—Misdescribed amendments [none]
Endnote 8—Miscellaneous [none]